Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | RHOC | P08134 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246732 | 0.84 | FFAR1 (0.45) | FFAR1PPARAFFAR4MAPTCACNA1B | |
| SCHEMBL3249812 | 0.81 | MEN1 (0.45) | FFAR1MAPTCYP2C19RHOCRHOA | |
| SCHEMBL3246798 | 0.79 | FFAR1 (0.55) | FFAR1PPARAFFAR4MAPTCACNA1B | |
| SCHEMBL3245006 | 0.77 | RHOC (0.44) | FFAR1PPARAFFAR4MAPTCYP3A4 | |
| SCHEMBL7345712 | 0.76 | FFAR1 (0.68) | FFAR1PPARAFFAR4MAPTCACNA1B | |
| SCHEMBL3249639 | 0.75 | MAPT (0.43) | FFAR1MAPTCYP3A4CYP2C19 | |
| SCHEMBL3240177 | 0.74 | NOS1 (0.41) | FFAR1PPARAFFAR4MAPTCACNA1B | |
| SCHEMBL5544782 | 0.72 | FFAR1 (0.55) | FFAR1PPARACACNA1BADRA2ACACNA1H | |
| SCHEMBL7102889 | 0.72 | FFAR1 (0.62) | FFAR1FFAR4MAPTCACNA1B | |
| SCHEMBL6557440 | 0.69 | FFAR1 (0.63) | FFAR1PPARAMAPTCACNA1BMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |